Detalhes bibliográficos
| Resumo: | Aim: To evaluate prostate-specific antigen response (PSAr) defined as a ≥50% decrease in PSA concentration from the pretreatment value, as a prognostic factor in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA). Methods: Retrospective evaluation of patients with mCRPC treated with AA. Results: 124 patients were identified. Median overall survival and progression-free survival for patients achieving PSAr versus patients without PSAr were 29.3 versus 9.7 months and 17.0 versus 5.2 months, respectively. Multivariate analysis confirmed that PSAr correlated with better overall survival (hazard ratio: 0.19; 95% CI: 0.10-0.38; p < 0.001) and progression-free survival (hazard ratio: 0.24; 95% CI: 0.14-0.41; p < 0.001). Conclusion: PSAr can be utilized as prognostic and predictive factors in mCRPC patients treated with AA. |
|---|
| Autores principais: | Alvim, Cecilia |
|---|
| Outros Autores: | Mansinho, André; Paiva, Rita S.; Brás, Raquel; Semedo, Patrícia M.; Lobo-Martins, Soraia; da Ponte, Carolina B.; Macedo, Daniela; Ribeiro, Maria Leonor; dos Reis, José P; Fernandes, Isabel; Costa, Luis |
|---|
| Assunto: | Abiraterone acetate Metastatic castration-resistant prostate cancer Prostate-specific antigen response |
|---|
| Ano: | 2020 |
|---|
| País: | Portugal |
|---|
| Tipo de documento: | artigo |
|---|
| Tipo de acesso: | acesso aberto |
|---|
| Instituição associada: | Universidade de Lisboa |
|---|
| Idioma: | inglês |
|---|
| Origem: | Repositório da Universidade de Lisboa |
|---|